Cardiol Therapeutics (NASDAQ:CRDL) is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a potential new drug application. Speaking at a Canaccord Genu

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Cardiol Therapeutics (CRDL.TO), up 3.6% in U.S. pre-market trading, is expanding its Phase 3 Maveric

Cardiol Therapeutics (NASDAQ:CRDL) is aiming to address inflammation-driven heart disease with therapies the company believes could improve outcomes in conditions that currently have limited or no approved treatment options, President and CEO David Elsley said in an interview with Barchart. Speakin

Cardiol Therapeutics (CRDL.TO) reported Wednesday a narrowed net loss for 2025, while saying it has

Cardiol Therapeutics (NASDAQ:CRDL) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its clinical development programs targeting inflammation in cardiac disease, with its most advanced asset, CardiolRx, currently being studied in a Phase III trial for recurrent pericardi

Cardiol Therapeutics Inc. ( TSE:CRDL ) is possibly approaching a major achievement in its business, so we would like to...

The Canadian market, while facing challenges such as trade uncertainties and emerging credit concerns, remains resilient with positive corporate earnings growth and potential interest rate cuts on the horizon. In this context, penny stocks—typically smaller or newer companies—continue to capture investor interest due to their affordability and growth potential. By focusing on those with strong balance sheets and solid fundamentals, these stocks can offer a unique opportunity for investors...

Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.